You approach this the wrong way round.
Why do we not have any patents protected at this stage of the game should be your question.
But I do not wish to be drawn into examples of milestone payments given by large companies prior to patent protection as it would be such a lengthy discussion and I feel that I spent enough time on this forum for this weekend.
Please research how companies protect promising research, how DPUs ( discovery performance units ) are treated by GSK within their new approach since 2008 for their innovative programs which was trend setting for the industry.
DPUs are intended to operate like a biotech company housed in a big pharma firm. Much as a biotech gets funded by venture capitalists, a DPU receives an initial bolus of money and then extra cash when certain project goals are met. Each DPU had an initial review after a year of operation and will undergo another review this month, the 18-month check point. The board meets a last time at the three-year mark.
This is something I had to hoped to see developed with GSK and certain funding details to be shared with market.
- Forums
- ASX - By Stock
- WFL
- would it be fair to say
would it be fair to say, page-49
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable